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The authors describe the current issues in the adjuvant
and neoadjuvant treatment of both clearly resectable and
borderline resectable adenocarcinomas of the pancreas.
After decades of conducting research in the treatment of
localized pancreas cancer, few trials have been conducted
and even fewer answers are available.
The consensus statement by Abrams et al.
1 focuses on
patients who are considered to have localized pancreas
cancer, but, in fact, while pancreas cancer may appear
localized on radiographic exam, most patients actually have
undetected systemic disease. Evidence for this comes from
recent adjuvant therapy trials in which those patients who
had R0 or R1 resections still had mortality rates of *90% at
5 years when treated with surgery alone (ESPAC-1 and
CONKO-001).
2,3Thefactthatcurrentadjuvanttherapy may
double the survival rates at 5 years provides little comfort to
the patients and their families since approximately 80% of
these ‘‘resectable’’ patients still do not survive this disease.
To be prepared for a time when more effective systemic
options exist, the authors of the consensus article look at the
best steps currently available.
First, to make results from various trials easier to
interpret, the language and conduct of clinical trials needs
to improve. In the postoperative, adjuvant setting it is
important that deﬁnitions of margin status are consistent
between trials and between institutions. For example, the
number of margins assessed may vary and how many slides
are evaluated at each site may differ. Institutions may take
alternative approaches to inking, or marking, the tumor
margins, which can be a difﬁcult task in a resected speci-
men. Different trials have signiﬁcant variations on
eligibility criteria, deﬁnitions of radiation ports, technique
for radiation, and criteria for supportive care of the pan-
creas cancer patient, all of which can affect outcome of the
trials. Without a common language for and approach to
clinical trials, new studies will continue to face serious
criticism, and more decades will pass without signiﬁcant
improvements in patient care.
To improve upon the current options for localized dis-
ease, a multidisciplinary approach is clearly necessary.
However, one key element to this approach, systemic
therapy, has not been effective in advanced disease. Gem-
citabine, the current standard cytotoxic agent, is minimally
effective in controlling disease, and the targeted agents that
have yielded hope in other cancers have provided little
beneﬁt in metastatic pancreas cancer. In fact, since the
approval of gemcitabine, only one systemic regimen, gem-
citabine ? erlotinib, has had a statistically signiﬁcant
beneﬁt for survival compared with gemcitabine alone.
4
However, there are still questions as to the clinical signiﬁ-
cance of the survival beneﬁt provided by adding erlotinib to
gemcitabine. Thus, researchers are left with limited options
for the next systemic step to improve control of disease.
Whether or not to add erlotinib to gemcitabine in the adju-
vant setting is one of the key questions being asked by the
currently planned intergroup adjuvant study designed by
the Radiation Therapy Oncology Group (RTOG) and the
Intergroup Task Force on Pancreas Cancer.
Based on the results of the trials reviewed, it is clear that
patients with resected pancreatic adenocarcinoma have
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DOI 10.1245/s10434-009-0412-ximproved survival with adjuvant therapy.
2,3,5 Compared
with no adjuvant therapy, systemic therapy resulted in
improved survival in both the ESPAC-1 trial and the
CONKO-001 trial.
2,3
The consensus statement is somewhat equivocal about
the results of RTOG 9704 relating to the primary endpoint
of survival in patients with pancreatic head carcinomas.
5
They correctly state that gemcitabine administered before
and after 5FU-based chemoradiation resulted in a statisti-
cally signiﬁcant improvement in overall survival on
multivariate analysis (at P = .05). The sentence following
this in the consensus statement reads ‘‘this survival dif-
ference was not statistically signiﬁcant.’’ It should read
‘‘this survival difference was not statistically signiﬁcant on
univariate analysis.’’ On a preplanned multivariate analy-
sis, the results for survival in patients with cancer of the
head of the pancreas reach statistical signiﬁcance with a P
value of exactly .05. It is important to note that the study
clearly deﬁned statistical signiﬁcance as a P value
of B .05. The multivariate analysis provides a more precise
estimate of the treatment effect, given that it adjusts for
known prognostic variables.
When controlling for patients with a low postresection
serum CA 19-9, as used in CONKO-001, the gemcitabine
arm of RTOG 9704 had a 2-month longer median survival
compared with CONKO-001, with the caveat that this is
comparing trials with very different designs. Moreover,
data from institutional trials, as well as retrospective
analysis and SEER analysis all suggest an improvement in
both disease-free and overall survival with the use of
radiation in the adjuvant setting. The more recent CONKO-
001 and the RTOG 9704 studies suggest the superiority of
a gemcitabine-based chemotherapy over a 5-FU based
regimen. Analysis of RTOG 9704 also demonstrated the
lowest local recurrence rate (23%) of any previously
reported Phase III adjuvant trial to date (previous range,
37%–63%). This result may be attributable to the fact that
RTOG 9704 was the ﬁrst Phase III adjuvant trial to require
prospective quality assurance (QA) of radiation therapy
(RT) planned for patients on study. In addition, review of
the data from RTOG 9704 demonstrated that RT delivery
‘‘per protocol’’ had a signiﬁcant impact on patient survival
and potential toxicity.
6 The effects of radiation are
encouraging, but as yet they remain to be absolutely pro-
ven. In Europe, a recent randomized Phase II study was
completed comparing gemcitabine alone with gemcitabine
plus radiation, but this will not proceed to a Phase III trial
because of a lack of funding. The second important ques-
tion being asked by the planned RTOG study (0848) to be
conducted in the United States, Canada, and Europe is
whether or not chemoradiation at the end of chemotherapy
provides survival beneﬁt. Ironically, presuming the suc-
cessful completion of the RTOG 0848 trial, if radiation
improves local control, but not survival, we may have to
revisit the radiation therapy question when better systemic
control is ﬁnally achieved.
It is also time to explore some options beyond surgery
followed by postoperative therapy for the localized pan-
creas cancer patient. Neoadjuvant approaches, while as yet
unproven by a Phase III trial, should ﬁgure prominently in
future clinical trials. The rationale for a neoadjuvant
approach has been enumerated by many. First, pancreas
cancer surgery has signiﬁcant risk for morbidity that may
prevent patients from receiving postoperative treatment
with either chemotherapy or chemoradiotherapy. A neo-
adjuvant approach would allow a higher percentage of
patients to receive multimodality treatments. Second, an
effective neoadjuvant approach should theoretically
improve the chances at achieving an R0 resection. Third,
with tumor still in place, smaller radiation ﬁelds may be
designed that theoretically will result in less short- and
long-term morbidities from radiation. Finally, it is theo-
retically possible that a neoadjuvant approach will ‘‘weed
out’’ the patients with the most aggressive, treatment-
resistant disease. These patients would progress during the
neoadjuvant treatment period and prevent them from
unnecessarily undergoing surgery and its attendant risks.
Unfortunately, current neoadjuvant therapy results are
limited to single-institution, nonrandomized studies.
Because patient selection can play a crucial role in Phase II
treatment results, multi-institutional studies with common
language and eligibility requirements are necessary.
Investigators will have to determine the best approach to
deﬁne potential resectability. Is triphasic computed
tomography (CT) scan with thin cuts alone sufﬁcient?
Should endoscopic ultrasound (EUS) be used for anything
more than biopsy? Do we need preoperative laparoscopy to
rule out peritoneal disease that is not well detected by any
current radiographic techniques? Next, the deﬁnitions of
resectable and borderline resectable need to be made more
consistent. Many issues remain controversial, such as: how
much of the superior mesenteric or hepatic artery can be
surrounded on CT before a tumor is deemed borderline
resectable or unresectable, or whether or not the need to
replace a segment of vein deﬁnes a resectable or borderline
resectable status.
With parallel study of both neoadjuvant and postoper-
ative adjuvant approaches, treatment sequencing might
become an important future issue of study. A prospective,
randomized trial comparing preoperative with postopera-
tive therapy would not be easy. Patients would need to
register and undergo laparoscopy before randomization,
thus obliging surgeons to agree to participate and to discuss
the alternatives. Those developing systemic metastases
during neoadjuvant therapy and those found at both the
surgery-ﬁrst and surgery-second arms to have unresectable
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statistical design. Qualify of life (QOL) and cost analyses
would be important secondary endpoints of such a study.
Most importantly, this question has been difﬁcult to ask in
the past with only one of three trials asking the same type
of question successfully completing accrual in rectal
cancer.
Finally, the authors of the consensus article also address
one of the most difﬁcult issues in localized pancreas can-
cer: the recently identiﬁed category of borderline resectable
patients.
1 For years, physicians treating pancreas cancer
have largely ignored the TNM staging to place patients in
three categories: resectable, locally advanced but unresec-
table, and metastatic. Now, with better radiographic
techniques and a renewed focus on surgeons with expertise
in pancreas cancer surgery, a fourth category has been
deﬁned radiographically. These patients need to be con-
sistently identiﬁed a priori as the goals of therapy differ
from the truly unresectable patients where shrinkage, no
matter how great, will not change the ability to perform
surgery (for example, the completely encased superior
mesenteric artery). We concur with the authors of the
consensus statement that deﬁnitions need to be uniform,
consistent, and clear. These patients need their own trials
that have endpoints such as treatment response and an
increase in the margin-negative resectability rate. The
ultimate goal in performing such studies is to determine if
in producing responses and/or improving R0 resection
rates, some patients are cured or can live disease- and
symptom-free for longer periods of time. If these patients
with intermediate prognoses are allowed into trials for
patients with either clearly resectable or clearly unresec-
table cancers, they should be identiﬁed, as their presence in
either cohort could affect the study results.
There are some areas where the guidelines for deﬁning
borderline resectable disease as outlined in the consensus
statement, right or wrong, may not have gone far enough.
First, it is clear that not all CT scanners are of the same
quality. While few, if any, nonspiral CT scan machines
exist within the United States, the number of slices
obtained at a time can still differ, and as technology con-
tinues to move forward, the number of millimeters between
each slice may also change, improving the ability to see the
vessel/tumor interface. Three-dimensional reconstructions
can be very helpful to the surgeon in determining resect-
ability, but this technique is not applied in every case or at
every institution. Finally, the expertise of the radiologists,
like the expertise of all physicians involved in the care of
pancreas cancer, is not uniform, and this variability may
lead to differences in the approach to the same patient at
multiple institutions. More work is needed to precisely
deﬁne what degree of portal/SMV impingement is
consistent with borderline resectability. Variability may
also be a signiﬁcant problem with the surgeons. As
unpleasant as it is to note that not all physicians have the
same level of skills, multiple papers suggest that practice is
important with regard to the pancreatoduodenectomy.
Physicians and institutions with high volumes appear to
have better outcomes than physicians and institutions with
low volumes for pancreas cancer.
7 However, the majority
of patients do not have their care given by high-volume
surgeons for practical reasons, and this problem does not
lend itself to an easy solution. However, in truly moving
forward with the care of these patients it is impossible to
ignore these data as it remains so consistent.
Finally, there are undoubtedly one or more biologic
factors that will more precisely deﬁne a group intermediate
to the resectable and unresectable than purely radiologic
parameters. Until they are discovered, radiologic tools are
the ones we must use and perfect in order to prescribe
optimal therapy.
In conclusion, the consensus article provides guidelines
upon which we can develop trials for treating localized
pancreas cancer.
1 With a common approach to this deadly
disease we will have a better chance to succeed in the
future.
REFERENCES
1. Abrams, RA, Lowy AM, O’Reilly EM, Wolff RA, Picozzi VJ,
Pisters PWT. Combined modality treatment of resectable and
borderline resectable pancreas cancer: Expert consensus statement.
Ann Surg Oncol. 2009; [Epub ahead of print]. DOI:10.1245/
s10434-009-0413-9.
2. Neoptolemos J P,Stocken DD, Friess H, Bassi C, Dunn JA, Hickey
H, et al. A randomized trial of chemoradiotherapy and chemo-
therapy after resection of pancreatic cancer. N Engl J Med.
2004;350:1200–10.
3. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K,
et al. Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative-intent resection of pancreatic cancer:
a randomized controlled trial. JAMA. 2007;297:267–77.
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S,
et al.: Erlotinib plus gemcitabine compared with gemcitabine alone
in patients with advanced pancreatic cancer: a phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 2007;25:1960–6.
5. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP,
Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before
and after ﬂuorouracil-based chemoradiation following resection of
pancreatic adenocarcinoma: a randomized controlled trial. JAMA.
2008;299:1019–26.
6. Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP,
Konski AA, et al. RTOG 97-04—Radiotherapy Quality Assurance
(QA) Review and Survival. Proceedings of ASTRO, Int J Radiat
Oncol Biol Phys. 2006;66:S22.
7. Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of
perioperative deaths to hospital volume among patients undergoing
pancreatic resection for malignancy. Ann Surg. 1995;225:638–45.
Combined Modality Treatment of Pancreatic Cancer 1759